1. Biosimilars in Immune-Related Diseases

2. Introduction

3. Anti-TNF Biosimilars Approved in EU

4. Upcoming Adalimumab Biosimilar Launches in Europe

5. Differences Between Biologics and Small Molecules

6. Biologic Manufacturing Process and Source of Variation

7. Key Features of Biosimilars -- EMA

8. Route to Approval: Biologics vs Biosimilars

9. Key Steps in the Biosimilar Development Process

10. The Concept of Extrapolation

11. The Concept of Extrapolation (cont)

12. Switching -- Expert Perspective

13. Importance of Communication Strategy in Switching

14. Meta-Analyses on Switching From Reference Medicines to Biosimilars

15. Switching -- Expert Practice Experience

16. Switching Patients From Originator to Biosimilar -- Rheumatology Experience

17. Switching Patients From Originator to Biosimilar -- Dermatology Experience

18. Position Statement on Biosimilars

19. Position Statement on Biosimilars -- Experts' Perspectives

20. Concluding Remarks

21. Concluding Remarks (cont)

22. Abbreviations